09:39 AM EST - Medicenna Therapeutics Corp. : Announced preliminary data from the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study of MDNA11, the Company’s selective, long-acting and novel IL-2 super-agonist. Medicenna Therapeutics Corp.
shares T.MDNA are trading unchanged at $2.20.
